> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# CBER Allowing Device ‘In-Person’ Meetings
- URL: https://www.fdaweb.com/cber-allowing-device-in-person-meetings/
- Published: 2023-08-08T12:00:00.000Z
- Updated: 2026-09-14T18:48:55.000Z
- Author: David McFarland
- Tags: Devices, #legacy-id-D5155045

CBER says it is now beginning a phased implementation of in-person industry meetings with device manufacturers. “At this time, CBER will limit in-person meetings to Submission Issue Requests,” according to an [agency notice](https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/device-submissions-cber-regulated-products?ref=fdaweb.com).

Now that CBER staff have begun returning (post-pandemic) to work at its White Oak, MD campus (on-site) for a portion of their time, in-person meetings are now permitted, the notice says. “To avoid overcrowding in the conference rooms, all in-person FTF \[face-to-face\] formal meetings will have a hybrid component (virtual attendees in addition to in-person attendees),” it explains. “FDA will focus on having only core participants with a primary speaking role in-person while others join virtually. FDA encourages industry to follow this same pattern.”

Additionally, FDA says its White Oak conference rooms are being upgraded, in phases, with new technology (e.g., noise-canceling, boom-forming microphones, face/conversation tracking video cameras). “The availability of hybrid conference rooms initially limits the number of in-person meeting requests that can be granted,” it says. “CBER will continue to frequently monitor conference room upgrades, and as additional rooms are completed, we will continue the expansion until all formal meeting types that would qualify for FTF can be requested as in-person.”